CliffBio
small molecule

BRIMONIDINE TARTRATE

BRIMONIDINE TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBRIMONIDINE TARTRATE
Active ingredientBRIMONIDINE TARTRATE
Strength0.15%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJanuary 2022
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.